A Benchmark of In-House Homologous Recombination Repair Deficiency Testing Solutions for High-Grade Serous Ovarian Cancer Diagnosis.

ABSTRACT: Homologous recombination deficiency (HRD) has become an important prognostic and predictive biomarker for patients with high-grade serous ovarian cancer who may benefit from poly-ADP ribose polymerase inhibitors (PARPi) and platinum-based therapies. HRD testing provides relevant information to personalize patients' treatment options and has been progressively incorporated into diagnostic laboratories. Here, we assessed the performance of an in-house HRD testing system deployable in a diagnostic clinical setting, comparing results from two commercially available next-generation sequencing (NGS)-based tumor tests (SOPHiA DDM^TM HRD Solution and AmoyDx^® (HRD Focus Panel)) with the reference assay from Myriad MyChoice^® (CDx). A total of 85 ovarian cancer samples

SUBMITTER: Guarischi-Sousa R 

PROVIDER: S-EPMC10648202 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature